PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Market segmentation by type of molecules
PART 07: Global protein therapeutics market
Introduction
Drivers, challenges, and trends
Market segmentation by type of molecules
PART 08: Global vaccines market
Introduction
Drivers, challenges, and trends
Market segmentation by end-user age group
PART 09: Global cell therapy market
Introduction
Drivers, challenges, and trends
Market size and forecast
PART 10: Geographical segmentation
Biologic therapeutics market in Americas
Biologic therapeutics market in EMEA
Biologic therapeutics market in APAC
PART 11: Market drivers
Reimbursement support for biologics
Promising drug pipeline
Focus on development of novel mechanisms
Increase in industry–academia collaborations
PART 12: Impact of drivers
PART 13: Market challenges
High cost of therapy
Stringent regulatory guidelines
Fierce market competition
Cold chain management
Poor diagnosis and screening
PART 14: Impact of drivers and challenges
PART 15: Market trends
Emergence of targeted and combination therapies
Increase in R&D
Shift in focus to untapped markets
Rise in public awareness
PART 16: Vendor landscape
Competitive scenario
Key news
Mergers and acquisitions
Market share analysis
Amgen
F. Hoffmann-La Roche
Novo Nordisk
Sanofi
Other and future prominent vendors
PART 17: Key vendor analysis
Amgen
F. Hoffmann-La Roche
Novo Nordisk
Sanofi
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Global biologic therapeutics market 2014-2019 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Global biologic therapeutics market segmentation by type of molecules
Exhibit 05: Global biologic therapeutics market segmentation by type of molecules 2014
Exhibit 06: Global biologic therapeutics market segmentation by type of molecules 2014-2019 ($ billions)
Exhibit 07: Key drivers and challenges of global protein therapeutics market
Exhibit 08: Key trends of global protein therapeutics market
Exhibit 09: Global protein therapeutics market 2014-2019 ($ billions)
Exhibit 10: Global protein therapeutics market 2014
Exhibit 11: Global protein therapeutics market by type of molecules 2014-2019 ($ billions)
Exhibit 12: Global monoclonal antibodies market 2014-2019 ($ billions)
Exhibit 13: Global enzymes market 2014-2019 ($ billions)
Exhibit 14: Global other protein therapeutics market 2014-2019 ($ billions)
Exhibit 15: Drivers of global vaccines market
Exhibit 16: Challenges of global vaccines market
Exhibit 17: Trends in global vaccines market
Exhibit 18: Global vaccines market 2014-2019 ($ billions)
Exhibit 19: Global vaccines market by end-user age group 2014
Exhibit 20: Global vaccines market by end-user age group 2014-2019 ($ billions)
Exhibit 21: Global pediatric vaccines market 2014-2019 ($ billions)
Exhibit 22: Global adult vaccines market 2014-2019 ($ billions)
Exhibit 23: Key factors influencing the global cell therapy market
Exhibit 24: Global cell therapy market 2014-2019 ($ billions)
Exhibit 25: Global biologic therapeutics market by geography 2014
Exhibit 26: Biologic therapeutics market in Americas 2014-2019 ($ billions)
Exhibit 27: Biologic therapeutics market in EMEA 2014-2019 ($ billions)
Exhibit 28: Biologic therapeutics market in APAC 2014-2019 ($ billions)
Exhibit 29: Global biologic therapeutics market by geography 2014-2019 ($ billions)
Exhibit 30: Impact of drivers
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Revenue of Enbrel 2012-2014 ($ millions)
Exhibit 33: Revenue of Epogen 2012-2014 ($ millions)
Exhibit 34: Revenue of Neulasta/Neupogen 2012-2014 ($ millions)
Exhibit 35: Revenue of vectibix 2012-2014 ($ millions)
Exhibit 36: Revenue of Xgeva 2012-2014 ($ millions)
Exhibit 37: Revenue of Prolia 2012-2014 ($ millions)
Exhibit 38: Revenue of Avastin 2012-2014 ($ millions)
Exhibit 39: Revenue of Kadcyla 2013 and 2014 ($ millions)
Exhibit 40: Revenue of Lucentis 2012-2014 ($ millions)
Exhibit 41: Revenue of Rituxan/MabThera 2012-2014 ($ millions)
Exhibit 42: Revenue of Pegasys 2012-2014 ($ millions)
Exhibit 43: Revenue of Perjeta 2013 and 2014 ($ millions)
Exhibit 44: Revenue of Pulmozyme 2012-2014 ($ millions)
Exhibit 45: Revenue of Pulmozyme 2012-2014 ($ millions)
Exhibit 46: Revenue of Apridra 2012-2014 ($ millions)
Exhibit 47: Revenue of Cerezyme 2012-2014 ($ millions)
Exhibit 48: Revenue of Fabrazyme 2012-2014 ($ millions)
Exhibit 49: Revenue of Myozyme/Lumizyme 2012-2014 ($ millions)
Exhibit 50: Revenue of Lantus 2012-2014 ($ millions)
Exhibit 51: Revenue of Zaltrap 2012-2014 ($ millions)
Exhibit 52: Amgen: Business segmentation by revenue 2014
Exhibit 53: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 54: Amgen: Geographical segmentation by revenue 2014
Exhibit 55: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 56: Novo Nordisk: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 57: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 58: Novo Nordisk: R&D expenditure 2014
Exhibit 59: Business segmentation by revenue 2013 and 2014 ($ billions)
【掲載企業】
Amgen, F. Hoffmann-La Roche, Novo Nordisk, Sanofi.
【資料のキーワード】
生物製剤治療、モノクローナル抗体、酵素、小分子、タンパク質治療、ワクチン、細胞治療、医療
【調査方法】
一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)